Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04368858
Other study ID # RBHP 2020 REYNAUD
Secondary ID 2020-A00290-39
Status Completed
Phase N/A
First received
Last updated
Start date August 28, 2020
Est. completion date November 16, 2022

Study information

Verified date November 2022
Source University Hospital, Clermont-Ferrand
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In patients with chronic illness, screening for falls and their health consequences are major public health issues. Muscle weakness, gait and balance disorders are among the most common risk factors for falling. Assessing these parameters would thus be a crucial step in the evaluation of the risk of falling, allowing to more precisely orient the management strategy. Combining inertial unit sensors with clinically validated tests can provide additional information to improve the assessment of fall risks. We therefore propose to constitute a monocentric exploratory study, testing a prognostic screening tool, in patients suffering from a chronic pathology, in order to assess the risk of falling in this population. Considering the relationship between muscle weakness and the risk of falling, we can assume that a deficit in muscle strength will result in less vertical acceleration which could point to a muscle cause of the balance disorder and thus allow a finer detection of the risk of falling. On the other hand, we hypothesize that spinal static disorders in chronic pathologies and in particular osteoarthritis, as well as balance disorders linked to impaired deep sensitivity lead to an increase in oscillations of the trunk when walking which can cause postural balance disorders thus increasing the risk of falling.


Description:

Investigators propose to constitute a prospective cohort of subjects carrying chronic disease. The main objective is to study the correlation between the vertical acceleration during the sit to stand phase of the instrumented Timed Up and Go test (TUG) and the isokinetic muscle strength of the quadriceps. In addition, as secondary objectives, we will study the potential correlations between the other parameters collected with the inertial sensors during instrumented tests (Timed-Up and Go test, and 6-Minute Walk Test) and the isokinetic muscle strength of the lower limb muscles, posturography parameters, gait parameters, apprehension of fall and others. In the present protocol, parameters will be measured once at inclusion day (to). Only the falling incidences will be collected prospectively at 6 months and at 1 year from the inclusion day. Statistical analyses will be carried out using Stata software (version 13, StataCorp, College Station, USA). Qualitative variables will be described in terms of numbers and associated percentages. The quantitative variables will be described in terms of numbers, associated mean and standard deviation, median and interquartile range. Wherever is possible, graphic representations will be associated with these analyses. All tests will be performed for a bilateral hypothesis and a p-value <5% will be considered statistically significant. For the main outcome, the Pearson correlation coefficient (or Spearman if data are not normally distributed) will be calculated with its 95% confidence interval. The analysis of the relationships between the continuous criteria will be carried out using Pearson correlation coefficients (or Spearman if data are not normally distributed). The search for fall risk factors (at 6 months / 1 year) will be carried out using standard tests: - Chi-square test (or exact Fisher test when appropriate) for the categorical criteria. - Student test (or Mann and Whitney test if data not normally distributed) for continuous criteria. These analyses will be completed using a logistic regression model by adjusting to the clinically relevant criteria or highlighted in the univariate analysis. Results will be presented as an odd ratio with their 95% confidence interval Little or no missing data is expected on the main criteria, however if a rate of missing data> 5% is observed, a sensitivity analysis for missing data will be carried out in order to characterize their nature (MCAR, MAR, MNAR) in order to propose the most suitable imputation method.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date November 16, 2022
Est. primary completion date November 16, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - Man or woman aged 18 to 90. - Patients with chronic pathology contributing to impaired mobility. - Volunteers who have given their written consent. - Affiliated to French health care system (for France) Exclusion Criteria: - Patients suffering from progressive psychiatric pathologies (active psychosis, hallucinations, etc.) or the presence of another serious unstabilized pathology (decompensated heart failure, progressive terminal cancer, etc.). - People with poorly controlled or unstable cardiovascular disease. - Major osteoarticular or neurological problems completely preventing the proper performance of the various tests. - Persons under guardianship, curatorship, deprived of liberty or safeguarding justice. - People refusing to participate. - Pregnant or lactating women.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Exploratory physiopathology study, including non-invasive functional explorations carried out in patients with chronic pathology.
In the Mobility Exploration Unit of the University Hospital of Clermont-Ferrand, patients with chronic illnesses undergo a complete assessment of their physical capacities as well as their nutritional status. For the purpose of this protocol, patients will have to perform 2 functional tests, namely the TM6 and the TUG, while being equipped with inertial sensor units (mTUG® and mGAIT®). The data of the gait analysis, posturography and strength analyses as well as the questionnaires' scores will be taken into account in this research. At 6 months and at 1 year, occurrence of a fall will be recorded in order to prospectively monitor this parameter.

Locations

Country Name City State
France Chu Clermont Ferrand Clermont-Ferrand

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Clermont-Ferrand

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Vertical acceleration in m/s² during the sit to stand phase of the Timed-Up and Go test. Vertical acceleration will be collected with the mTUG® inertial sensor unit. Day 0
Primary Maximum voluntary isokinetic strength (Nm) of the quadriceps muscles in slow speed (60°/s) concentric contraction. : Maximum voluntary isokinetic strength of the quadriceps muscles will be measured with the HUMA® /NORM™ device. Day 0
Secondary Demographics information Demographics information will be obtained using a single questionnaire including questions on age, gender, qualification, personal work status, ethnicity, life and occupational events. day 0
Secondary Weight (Kg). Weight will be measured with the medical body weight scale SECA® and according to the ISAK recommendations. day 0
Secondary Height (cm). Height will be measured with a wall mounted tape measure and according to the ISAK recommendations. day 0
Secondary Waist circumference (cm). Waist circumference will be measured with a medical body tape measure and according to the ISAK recommendations. day 0
Secondary Hip circumference (cm). Hip circumference will be measured with a medical body tape measure and according to the ISAK recommendations. day 0
Secondary Brachial circumference (cm). Brachial circumference will be measured with a medical body tape measure and according to the ISAK recommendations. day 0
Secondary Calf circumference (cm). Calf circumference will be measured with a medical body tape measure and according to the ISAK recommendations. day 0
Secondary Body Mass Index (Kg/m²). Description: BMI will be calculated (weight in kilograms divided by height in meters squared). day 0
Secondary Body composition. Body composition (muscle and fat) will be measured using he Bodystat® Impedance-meter. day 0
Secondary Self-Reported Number of Falls during the previous year Number of falls will be evaluated with the Elderly Fall Screening Test (EFST). day 0
Secondary Self-Reported Number of Falls during the previous year Number of falls will be evaluated with the Elderly Fall Screening Test (EFST). Month 6
Secondary Self-Reported Number of Falls during the previous year Number of falls will be evaluated with the Elderly Fall Screening Test (EFST). Year 1
Secondary Sarcopenia risk. Sarcopenia risk will be evaluated with the SARC-F Questionnaire. Day 0
Secondary Balance confidence in performing various activities Self-report balance confidence will be evaluated with the Activities-specific Balance Confidence (ABC) Scale. Day 0
Secondary Maximum voluntary isometric strength of the quadriceps muscles at 45° (Nm). : Maximum voluntary isometric strength of the quadriceps muscles will be measured with the HUMA® /NORM™ device. Day 0
Secondary Maximum voluntary isokinetic strength of the quadriceps muscles at 60°/s (Nm). Maximum voluntary isokinetic strength of the quadriceps muscles at 60°/s will be measured with the HUMA® /NORM™ device. Day 0
Secondary Maximum voluntary isokinetic strength of the quadriceps muscles at 240°/s (Nm). Maximum voluntary isokinetic strength of the quadriceps muscles at 240°/s will be measured with the HUMA® /NORM™ device. Day 0
Secondary Maximum voluntary isokinetic strength of the quadriceps muscles at 30°/s (eccentric contraction) (Nm). Maximum voluntary isokinetic strength of the quadriceps muscles at 30°/s will be measured with the HUMA® /NORM™ device. Day 0
Secondary Maximum voluntary isokinetic strength of the hamstring muscles at 60°/s (Nm). Maximum voluntary isokinetic strength of the hamstring muscles at 60°/s will be measured with the HUMA® /NORM™ device. Day 0
Secondary Maximum voluntary isokinetic strength of the hamstring muscles at 240°/s (Nm). Maximum voluntary isokinetic strength of the hamstring muscles at 240°/s will be measured with the HUMA® /NORM™ device. Day 0
Secondary Maximum voluntary isokinetic strength of the hamstring muscles at 30°/s (eccentric contraction) (Nm). Maximum voluntary isokinetic strength of the hamstring muscles at 30°/s will be measured with the HUMA® /NORM™ device. Day 0
Secondary Statokinesigram surface area (mm²). Statokinesigram surface area will be measured with the STATIPRO® static posturography platform. Day 0
Secondary Stabilogram length (mm). Stabilogram length will be measured with the STATIPRO® static posturography platform. Day 0
Secondary Maximal deflection (forward, backward left and right). Maximal deflection will be measured with the STATIPRO® static posturography platform. Day 0
Secondary Velocity variations (mm/s). Velocity variations will be measured with the STATIPRO® static posturography platform. Day 0
Secondary Romberg ratio according to sway area Romberg ratio will be measured with the STATIPRO® static posturography platform day 0
Secondary Romberg ratio according to center of pressure path length. Romberg ratio will be measured with the STATIPRO® static posturography platform. day 0
Secondary Plantar pressure ratio sway area. : Plantar pressure ratio sway area will be measured with the STATIPRO® static posturography platform day 0
Secondary Plantar pressure ratio length Plantar pressure ratio length will be measured with the STATIPRO® static posturography platform. day 0
Secondary Walking velocity (cm/s). Walking velocity will be measured with the GAITRite® Electronic Walkway. day 0
Secondary Cadence (steps/min). Cadence will be measured with the GAITRite® Electronic Walkway. day 0
Secondary Step length (left and right foot) (cm) : Step length will be measured with the GAITRite® Electronic Walkway. day 0
Secondary Stride length (cm). Stride length will be measured with the GAITRite® Electronic Walkway. day 0
Secondary : Single support time left and right foot (% of walking cycle) Single support time will be measured with the GAITRite® Electronic Walkway. day 0
Secondary Double support time (% of walking cycle). Double support time will be measured with the GAITRite® Electronic Walkway. day 0
Secondary Swing time (% of walking cycle). : Swing time will be measured with the GAITRite® Electronic Walkway. day 0
Secondary Swing phase (% of walking cycle). Swing phase will be measured with the GAITRite® Electronic Walkway. day 0
Secondary Stance phase (% of walking cycle). : Stance phase will be measured with the GAITRite® Electronic Walkway. day 0
Secondary Functional capacity Timed-Up and Go Functional capacity will be evaluated using the Timed-Up and Go test. day 0
Secondary Functional capacity TDM6 Functional capacity will be evaluated using the 6-minute walk test. day 0
Secondary Vertical acceleration (m/s²) during the sit to stand phase of the Timed-Up and Go test (TUG). Vertical acceleration will be measured with the mTUG® inertial sensor unit. day 0
Secondary Time (s) to complete the Timed-Up and Go test. Time will be measured with the mTUG® inertial sensor unit. day 0
Secondary Anteroposterior acceleration (m/s2) during stand to walk phase of the Timed-Up and Go test Anteroposterior acceleration will be measured with the mTUG® inertial sensor unit. day 0
Secondary Vertical angular speed (m/s) during the TUG test. Vertical angular speed will be measured with the mTUG® inertial sensor unit. day 0
Secondary Medio-lateral angular velocity (m/s) during the TUG test. Medio-lateral angular velocity (m/s) will be measured with the mTUG® inertial sensor unit. day 0
Secondary Time (s) of the 180° rotation phase during the TUG test. Time of the rotation phase will be measured with the mTUG® inertial sensor unit day 0
Secondary Time (s) to pass from the sitting position to the first step during the TUG test. Time will be measured with the mTUG® inertial sensor unit. day 0
Secondary Duration (s) of the turn to sit phase during the TUG test. Time will be measured with the mTUG® inertial sensor unit. day 0
Secondary Total number of steps during the TUG test. Steps will be measured with the mTUG® inertial sensor unit. day 0
Secondary Average length of steps (m) during the TUG test. Steps will be measured with the mTUG® inertial sensor unit. day 0
Secondary Average walking speed (m/s) during the TUG test. Walking speed will be measured with the mTUG® inertial sensor unit. day 0
Secondary Number of steps during the 180° rotation phase of the TUG test. Steps will be measured with the mTUG® inertial sensor unit. day 0
Secondary Standard deviation of the duration of the step (s) during the TUG test. Standard deviation will be measured with the mTUG® inertial sensor unit. day 0
Secondary Spatio-temporal gait parameters (Average walking speed, step and stride length (right and left), cadence variability, variability in stride length, stance and swing phase, …) during the 6-minute Walk Test (6MWT). Spatio-temporal gait parameters will be measured with the mGAIT® inertial unit sensors day 0
See also
  Status Clinical Trial Phase
Completed NCT05415774 - Combined Deep Brain Stimulation in Parkinson's Disease N/A
Recruiting NCT04691661 - Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease Phase 2
Active, not recruiting NCT05754086 - A Multidimensional Study on Articulation Deficits in Parkinsons Disease
Completed NCT04045925 - Feasibility Study of the Taïso Practice in Parkinson's Disease N/A
Recruiting NCT04194762 - PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation N/A
Completed NCT02705755 - TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05830253 - Free-living Monitoring of Parkinson's Disease Using Smart Objects
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Recruiting NCT06139965 - Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
Completed NCT04580849 - Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease N/A
Completed NCT03980418 - Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam N/A
Completed NCT04477161 - Effect of Ketone Esters in Parkinson's Disease N/A
Completed NCT04942392 - Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic N/A
Terminated NCT03446833 - LFP Beta aDBS Feasibility Study N/A
Completed NCT03497884 - Individualized Precise Localization of rTMS on Primary Motor Area N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT04997642 - Parkinson's Disease and Movement Disorders Clinical Database
Completed NCT04117737 - A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson N/A
Recruiting NCT03618901 - Rock Steady Boxing vs. Sensory Attention Focused Exercise N/A